Advertisement

Topics

Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS

12:08 EST 27 Dec 2018 | Investing News Network

Spectrum Pharmaceuticals (Nasdaq:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that the company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ROLONTIS® (eflapegrastim). As quoted in the press release: “ROLONTIS is an important and significant … Continued

The post Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS appeared first on Investing News Network.

Original Article: Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS

NEXT ARTICLE

More From BioPortfolio on "Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...